Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Consensus Recommendation of “Reduce” by Analysts

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has been given an average recommendation of “Reduce” by the six research firms that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $30.00.

Several analysts have issued reports on FMS shares. Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Bank of America downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. Zacks Research lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.9%

Shares of FMS opened at $23.88 on Tuesday. The company has a 50-day moving average of $24.30 and a two-hundred day moving average of $25.52. The company has a current ratio of 1.36, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. Fresenius Medical Care AG & Co. KGaA has a one year low of $22.05 and a one year high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The business had revenue of $5.73 billion for the quarter, compared to analyst estimates of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. As a group, equities analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. US Bancorp DE raised its position in Fresenius Medical Care AG & Co. KGaA by 225.5% during the second quarter. US Bancorp DE now owns 75,660 shares of the company’s stock valued at $2,162,000 after acquiring an additional 52,418 shares in the last quarter. ABC Arbitrage SA increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 18.2% during the 2nd quarter. ABC Arbitrage SA now owns 229,375 shares of the company’s stock worth $6,553,000 after purchasing an additional 35,314 shares during the last quarter. Advisors Asset Management Inc. increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 243.3% during the 1st quarter. Advisors Asset Management Inc. now owns 7,817 shares of the company’s stock worth $195,000 after purchasing an additional 5,540 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 26.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 373,961 shares of the company’s stock valued at $10,684,000 after purchasing an additional 78,956 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 5.0% in the 1st quarter. Northern Trust Corp now owns 380,251 shares of the company’s stock valued at $9,468,000 after purchasing an additional 18,061 shares during the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.